Skip to main content

Table 2 Adjusted efficacy outcome measures in patients with or without enthesitis at baseline

From: Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

Outcome measuresWeekWith enthesitis at baselineWithout enthesitis at baseline
SecukinumabPlacebo (N = 163)SecukinumabPlacebo (N = 72)
300 mg (N = 144)150 mg (N = 159)300 mg (N = 95)150 mg (N = 79)
ACR20a,b1651.644.319.548.860.413.8
10455.259.157.659.8
ACR50a,b1631.421.07.532.632.94.1
10443.425.743.528.9
ACR70a,b1620.510.72.923.418.51.4
10426.717.032.818.9
PASI 90a,c1666.551.813.156.448.910.8
10446.234.952.524.8
PASI 75a,c1682.362.010.668.159.87.3
10488.587.495.580.1
HAQ-DId16− 0.5− 0.3− 0.2− 0.4− 0.5− 0.2
104− 0.4− 0.3− 0.5− 0.5
SF-36 PCSd166.13.52.36.17.02.0
1046.94.06.36.0
DAS28-CRPd16− 1.4− 1.0− 0.5− 1.3− 1.5− 0.4
104− 1.7− 1.5− 1.9− 1.7
  1. Logistic regression (for binary variables) or ANCOVA (for continuous variables) were performed as a function of the patient characteristics at baseline (treatment group, enthesitis status, gender, DAS28-CRP, HAQ-DI, TNFi-status), and the interaction between treatment groups and enthesitis status
  2. ACR American College of Rheumatology, DAS28-CRP; 28-Joint Disease Activity Score count using C-reactive protein, HAQ-DI Health Assessment Questionnaire Disability Index, LS least square, n number of evaluable patients, N total number of patients, PASI Psoriasis Area and Severity Index, SF-36 PCS Short Form 36 Physical Component Summary score
  3. aResponse, %
  4. bAt week 16/104, n = 144/132 (secukinumab 300 mg), 159/145 (secukinumab 150 mg), and 163 (placebo) with enthesitis and n = 95/91 (secukinumab 300 mg), 79/70 (secukinumab 150 mg), and 72 (placebo) without enthesitis at baseline
  5. cAt week 16/104, n = 66/56 (secukinumab 300 mg), 82/62 (secukinumab 150 mg), and 63 (placebo) with enthesitis and n = 38/34 (secukinumab 300 mg), 46/36 (secukinumab 150 mg), and 30 (placebo) without enthesitis at baseline (psoriasis subset)
  6. dLS mean change from baseline